

[4,4'-D-Diaminopropionic acid]gramicidin S: a synthetic gramicidin S analog with antimicrobial activity against Gram-negative bacteria

Shoji Ando, Haruhiko Aoyagi, Susumu Shinagawa*, Norikazu Nishino[†], Michinori Waki, Tetsuo Kato[†] and Nobuo Izumiya

Laboratory of Biochemistry, Faculty of Science, Kyushu University 33, Higashiku, Fukuoka 812, *Central Research Division, Takeda Chemical Industries, Ltd., Yodogawaku, Osaka 532 and [†]Department of Industrial Chemistry, Kyushu Institute of Technology, Tobataku, Kitakyushu 804, Japan

Received 4 July 1983

Gramicidin S is especially active against Gram-positive bacteria; e.g., *Staphylococcus aureus*. An analog, [4,4'-D-diaminopropionic acid]gramicidin S, which contains D-diaminopropionic acid residues instead of D-phenylalanine residues, has been synthesized. This analog is active against some of the Gram-negative bacteria; e.g., *Escherichia coli* and *Salmonella typhosa*. Activities of several related analogs are discussed.

Gramicidin S Gram-negative bacteria Peptide antibiotic Peptide synthesis
Structure-activity relationship

1. INTRODUCTION

Gramicidin S (fig.1) is a cyclic decapeptide antibiotic and exhibits high activity against Gram-positive bacteria such as *Bacillus subtilis* and *Staphylococcus aureus* [1]. Its decapeptide backbone holds a rigid β -sheet structure stabilized with 4 intramolecular hydrogen bonds as shown in fig.1. This conformation gives a cationic detergent-like character to the peptide [2]. In the course of studies on structure-activity relationships of gramicidin S, we synthesized analogs containing D-2,3-diaminopropionic acid (D-A₂pr) residues at 4,4' positions in order to study the role of two additional cationic residues on antibacterial

activity. We synthesized also an analog containing α,β -dehydroalanine (Δ Ala) residues at 4,4' positions from the analog containing D-A₂pr residues.

2. EXPERIMENTAL

Molecular mass was determined on a JEOL JMS-DX 300 mass spectrometer. CD spectra were recorded on a JASCO J-40A automatic recording spectropolarimeter in methanol.

The route for the synthesis of [L-Orn(HCO)^{2,2'}, D-A₂pr(Z)^{4,4'}]gramicidin S is shown in fig.2. The peptide chain was elongated stepwise by use of Boc-amino acid active ester and successive TFA treatment until protected pentapeptide I was obtained. The C-terminus in intermediate linear pentapeptide was N^ε-formyl-L-ornithine. One half of compound I was converted to active ester II, and another half was treated with TFA to give pentapeptide trifluoroacetate III-TFA. Coupling of II with III afforded decapeptide (IV) (82%), which was again converted to active ester, treated with TFA, and then

[†] To whom correspondence should be addressed

Abbreviations: see IUPAC-IUB Commissions (1974) Pure Appl. Chem. 40, 317-331; Others: EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; HO-NSu, N-hydroxysuccinimide; TFA, trifluoroacetic acid




Fig.1. Structure of gramicidin S.

	L-Leu	D-A ₂ pr	L-Pro	L-Val	L-Orn		L-Leu	D-A ₂ pr	L-Pro	L-Val	L-Orn
Boc		Z			HCO						
			EDC-HONSu		OH (I)						
Boc		Z			HCO						HCO
					ONSu (II)	H		Z			OH·TFA (III·TFA)
Boc		Z			HCO			Z			HCO
					EDC-HONSu						OH (IV)
Boc		Z			HCO			Z			HCO
					TFA						ONSu
H		Z			HCO			Z			HCO
					pyridine						ONSu·TFA (V·TFA)
cyclol		Z			HCO			Z			HCO
) (VI)

Fig.2. Synthesis of [L-Orn(HCO)^{2,2'}, D-A₂pr(Z)^{4,4'}]gramicidin S.

subjected to cyclization in pyridine at 3 mM of V. Purification with Amberlite CG-50, Dowex 1, and silica gel column chromatography yielded [L-Orn(HCO)^{2,2'}, D-A₂pr(Z)^{4,4'}]gramicidin S(VI) (39% from IV).

Treatment of VI with 0.5 M HCl in methanol for 3 days gave [D-A₂pr(Z)^{4,4'}]gramicidin S-2 HCl (VII-2 HCl) (75%, M_r (m + 1)⁺ 1288, calcd

(m + 1)⁺1288). Hydrogenolysis of VII removed the Z groups to give [D-A₂pr^{4,4'}]gramicidin S-4 HCl (VIII-4 HCl) (76%). Treatment of VII with (Boc)₂O [3] afforded [L-Orn(Boc)^{2,2'}, D-A₂pr(Z)^{4,4'}]gramicidin S (IX) (52%). Hydrogenolysis of IX gave [L-Orn(Boc)^{2,2'}, D-A₂pr^{4,4'}]gramicidin S-2 HCl (X-2 HCl) (95%), which was treated with CH₃I and KHCO₃ as in [4,5] to give

Table 1
Antimicrobial activity of gramicidin S analogs

Organism	Minimum inhibitory concentration ($\mu\text{g/ml}$)				
	GS	VII	VIII	X	XII
<i>Staphylococcus aureus</i> FDA 209P	6.25	6.25	100	>100	12.5
<i>Bacillus subtilis</i> PCI 219	3.13	3.13	12.5	>100	6.25
<i>Escherichia coli</i> NIHJ JC-2	>100	>100	25	>100	>100
<i>Salmonella typhosa</i> Boxhill 58	>100	>100	25	>100	>100
<i>Shigella flexneri</i> EW-10	6.25	6.25	25	>100	50
<i>Shigella sonnei</i> EW-33	100	>100	50	>100	100
<i>Klebsiella pneumoniae</i> DT	12.5	50	50	>100	25
<i>Proteus vulgaris</i> IFO 3988	>100	>100	>100	>100	>100

[L-Orn(Boc)^{2,2'}, $\Delta\text{Ala}^{4,4'}$]gramicidin S (XI) (74%). This was treated with TFA to yield [$\Delta\text{Ala}^{4,4'}$]gramicidin S-2 TFA (XII-2 TFA) (88%). All crystalline compounds gave satisfactory elemental analyses.

3. RESULTS

Results of the microbial assay are shown in table 1. Gramicidin S and compound VII show similar activities against Gram-positive bacteria and *Shigella flexneri*. On the other hand, compound VIII shows moderate activity against several Gram-negative bacteria including *Escherichia coli* but negligible activity against Gram-positive bacteria such as *Staphylococcus aureus*. Unexpectedly, compound XII shows high activity comparable to that of gramicidin S.

Fig.3 shows CD curves of gramicidin S and synthesized analogs. Characteristic features (troughs at about 205 and 215 nm) for gramicidin S are essentially preserved for VII, VIII and X. However, the intensity of the troughs was considerably decreased for VIII. Proximity of the 4 cationic charges may cause some disturbance in the backbone conformation. The CD curve of XII shows a trough at 222 nm, signifying change in conformation due to incorporation of ΔAla residues.

4. DISCUSSION

Dozens of amino acid-substituted analogs are synthesized for gramicidin S. All active analogs hold similar cationic detergent-like characters [2]. Analogs containing D-A₂pr residues also conserve the common character as suggested by similarity of CD curves. Complete inactivity of X suggests that the side-chain length of D-A₂pr is too short to interact with bacteria.




Fig.3. CD curves of gramicidin S analogs. Solvent: MeOH. Curve: (—) gramicidin S; (---) VII; (-·-·-) VIII; (-·-·-·-) X; (-·-·-·-·-) XII.

Compound VIII showed activity against some of Gram-negative bacteria. As the conformations of VIII and gramicidin S seem to be similar, the change in the activity should be due to the increase of cationic charges at the hydrophilic side of the molecule. It should be noted here that polymyxins, known by their high activity against Gram-negative bacteria, contain 6 basic amino acid residues out of 10 component amino acid residues [6].

REFERENCES

- [1] Gause, G.F. and Brazhnikova, M.G. (1944) *Am. Rev. Soviet Med.* 2, 134–138.
- [2] Izumiya, N., Kato, T., Aoyagi, H., Waki, M. and Kondo, M. (1979) in: *Synthetic Aspects of Biologically Active Cyclic Peptides – Gramicidin S and Tyrocidines*, Kodansha, Tokyo and Wiley, New York.
- [3] Moroder, L., Hallett, A., Wünsch, E., Keller, O. and Wersin, G. (1976) *Hoppe-Seyler's Z. Physiol. Chem.* 357, 1651–1653.
- [4] Kanmera, T. and Izumiya, N. (1982) *Int. J. Pept. Protein Res.* 19, 79–87.
- [5] Nomoto, S., Sano, A. and Shiba, T. (1979) *Tetrahedron Lett.* 521–522.
- [6] Suzuki, T., Hayashi, K., Fujikawa, K. and Tsukamoto, K. (1963) *J. Biochem.* 54, 555–556.